Bayer sees growth in animal health; Merck launches first transdermal BRD drug;

> Bayer announced that third-quarter sales in its animal health division rose 4.1% to €330 million ($415.2 million), led by sales of Advantage and Seresto flea and tick products. Release

> Merck ($MRK) Animal Health launched Finadyne Transdermal, the first transdermal drug to reduce fever associated with with bovine respiratory disease (BRD). Release

> The Canadian pet market has seen sales growth of 4% a year for the past 5 years, driven largely by investments in animal health by players like Bayer and Perrigo ($PRGO), according to a new report from Packaged Facts. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…